Skip to main content

A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC)

Open
  • Protocol code: CLIN-60190-453
  • EudraCT code: 2022-002695-37
  • Research group: Liver Diseases
  • Service: Hepatology
  • Principal investigator:  Campos Varela, Isabel
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase II
  • Status: Recruiting volunteers